市場調査レポート

商品コード

1439207

PARP阻害剤の世界市場の評価：薬剤タイプ別、用途別、エンドユーザー別、流通チャネル別、地域別、機会、予測（2017年～2031年）

PARP Inhibitors Market Assessment, By Drug Type, By Application, By End-user, By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年02月28日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 227 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のPARP阻害剤の市場規模は、予測期間中にCAGR 13.31％で成長し、2023年の64億4,000万米ドルから、2031年には175億米ドルに成長すると予測されています。

R&D活動への投資の増加と癌の有病率の増加が、市場に有利な成長機会をもたらしています。

癌の有病率の増加により、PARP阻害剤の有効性向上への注力が強化されるようになり、市場の拡大を後押ししています。米国癌協会によると、2023年には米国で新たに195万8,310人の癌患者が発生し、60万9,820人が癌関連で死亡すると推定されています。

National Breast Cancer Foundationによると、女性の8人に1人が乳癌と診断されます。2023年には、女性297,790人、男性2,800人が浸潤性乳癌と診断されると推定されています。PARP阻害剤は、癌細胞が傷ついた腫瘍DNAを修復するのを阻害します。オラパリブは早期乳癌と転移性乳癌の両方の治療に使用され、タラゾパリブは転移性乳癌の治療に使用されます。

地域別では、北米が大きな市場シェアを占める見込みです。この地域における主要企業の存在感、スキルを有する人材のアベイラビリティ、医療部門を強化するための政府のイニシアティブの増加、研究機関と市場参入事業者の双方によるR&D活動への投資の増加が北米のPARP阻害剤市場の成長を支えています。また、米国のさまざまな規制機関は、新規癌治療薬の効果の研究と承認を付与に注力しています。

当レポートでは、世界のPARP阻害剤の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
薬剤タイプ別
- オラパリブ
- ニラパリブ
- ルカパリブ
- タラゾパリブ
- ベリパリブ
- その他
用途別
- 卵巣癌
- 乳癌
- 膵臓癌
- 前立腺癌
エンドユーザー別
- 専門クリニック
- 病院
- 在宅医療
- その他
流通チャネル別
- 病院薬局
- 小売薬局
- オンライン薬局
地域別
- 北米
- 欧州
- アジア太平洋
- 南米
- 中東・アフリカ
企業別市場シェア

第5章世界のPARP阻害剤市場の展望：地域別

北米
欧州
アジア太平洋
南米
中東・アフリカ

第6章市場マッピング

薬剤タイプ別
用途別
エンドユーザー別
地域別

第7章マクロ環境と産業構造

需給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長抑制要因（課題、抑制要因）

第9章規制の枠組みとイノベーション

特許の情勢
規制当局の承認
イノベーション/最新技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (参入5社)
特許分析 (該当する場合)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Pfizer, Inc.
GlaxoSmithKline Plc.
Genentech, Inc.
AbbVie Inc.
Sierra Oncology, Inc.
Ono Pharmaceutical Co. Ltd.
Johnson & Johnson Services, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Repare Therapeutic, Inc.
Karyopharm Therapeutics Inc.

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 2. Global PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 3. Global PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 4. Global PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 5. Global PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 6. Global PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 7. Global PARP Inhibitors Market Share (%), By Region, 2017-2031F
Figure 8. North America PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 9. North America PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 10. North America PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 11. North America PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 12. North America PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 13. North America PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 14. North America PARP Inhibitors Market Share (%), By Country, 2017-2031F
Figure 15. United States PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 16. United States PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 17. United States PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 18. United States PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 19. United States PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 20. United States PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 21. Canada PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 22. Canada PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 23. Canada PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 24. Canada PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 25. Canada PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 26. Canada PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 27. Mexico PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 28. Mexico PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 29. Mexico PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 30. Mexico PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 31. Mexico PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 32. Mexico PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 33. Europe PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 34. Europe PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 35. Europe PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 36. Europe PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 37. Europe PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 38. Europe PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 39. Europe PARP Inhibitors Market Share (%), By Country, 2017-2031F
Figure 40. Germany PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 41. Germany PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 42. Germany PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 43. Germany PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 44. Germany PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 45. Germany PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 46. France PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 47. France PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 48. France PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 49. France PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 50. France PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 51. France PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 52. Italy PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 53. Italy PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 54. Italy PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 55. Italy PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 56. Italy PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 57. Italy PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 58. United Kingdom PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 59. United Kingdom PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 60. United Kingdom PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 61. United Kingdom PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 62. United Kingdom PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 63. United Kingdom PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 64. Russia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 65. Russia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 66. Russia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 67. Russia PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 68. Russia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 69. Russia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 70. Netherlands PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 71. Netherlands PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 72. Netherlands PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 73. Netherlands PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 74. Netherlands PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 75. Netherlands PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 76. Spain PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 77. Spain PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 78. Spain PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 79. Spain PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 80. Spain PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 81. Spain PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 82. Turkey PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 83. Turkey PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 84. Turkey PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 85. Turkey PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 86. Turkey PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 87. Turkey PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 88. Poland PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 89. Poland PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 90. Poland PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 91. Poland PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 92. Poland PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 93. Poland PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 94. South America PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 95. South America PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 96. South America PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 97. South America PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 98. South America PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 99. South America PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 100. South America PARP Inhibitors Market Share (%), By Country, 2017-2031F
Figure 101. Brazil PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 102. Brazil PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 103. Brazil PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 104. Brazil PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 105. Brazil PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 106. Brazil PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 107. Argentina PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 108. Argentina PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 109. Argentina PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 110. Argentina PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 111. Argentina PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 112. Argentina PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 113. Asia-Pacific PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 114. Asia-Pacific PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 115. Asia-Pacific PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 116. Asia-Pacific PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 117. Asia-Pacific PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 118. Asia-Pacific PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 119. Asia-Pacific PARP Inhibitors Market Share (%), By Country, 2017-2031F
Figure 120. India PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 121. India PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 122. India PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 123. India PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 124. India PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 125. India PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 126. China PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 127. China PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 128. China PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 129. China PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 130. China PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 131. China PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 132. Japan PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 133. Japan PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 134. Japan PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 135. Japan PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 136. Japan PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 137. Japan PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 138. Australia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 139. Australia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 140. Australia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 141. Australia PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 142. Australia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 143. Australia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 144. Vietnam PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 145. Vietnam PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 146. Vietnam PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 147. Vietnam PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 148. Vietnam PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 149. Vietnam PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 150. South Korea PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 151. South Korea PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 152. South Korea PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 153. South Korea PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 154. South Korea PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 155. South Korea PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 156. Indonesia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 157. Indonesia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 158. Indonesia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 159. Indonesia PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 160. Indonesia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 161. Indonesia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 162. Philippines PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 163. Philippines PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 164. Philippines PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 165. Philippines PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 166. Philippines PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 167. Philippines PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 168. Middle East & Africa PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 169. Middle East & Africa PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 170. Middle East & Africa PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 171. Middle East & Africa PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 172. Middle East & Africa PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 173. Middle East & Africa PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 174. Middle East & Africa PARP Inhibitors Market Share (%), By Country, 2017-2031F
Figure 175. Saudi Arabia PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 176. Saudi Arabia PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 177. Saudi Arabia PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 178. Saudi Arabia PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 179. Saudi Arabia PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 180. Saudi Arabia PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 181. UAE PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 182. UAE PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 183. UAE PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 184. UAE PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 185. UAE PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 186. UAE PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 187. South Africa PARP Inhibitors Market, By Value, In USD Billion, 2017-2031F
Figure 188. South Africa PARP Inhibitors Market, By Volume, In Million Units, 2017-2031F
Figure 189. South Africa PARP Inhibitors Market Share (%), By Drug Type, 2017-2031F
Figure 190. South Africa PARP Inhibitors Market Share (%), By Application, 2017-2031F
Figure 191. South Africa PARP Inhibitors Market Share (%), By End-user, 2017-2031F
Figure 192. South Africa PARP Inhibitors Market Share (%), By Distribution Channel, 2017-2031F
Figure 193. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11043

Global PARP inhibitors market is projected to witness a CAGR of 13.31% during the forecast period 2024-2031, growing from USD 6.44 billion in 2023 to USD 17.5 billion in 2031F. Increased investments in research and development activities and the increasing prevalence of cancer are providing lucrative growth opportunities to the market.

Poly (ADP-ribose) polymerase (PARPs) catalyze the transfer of ADP-ribose in proteins. PARP1 and PARP2 mediate the DNA repair process and play an essential role in maintaining genomic stability. PARP inhibitors prevent cancer cells from repairing, causing their death. These drugs mostly avoid affecting healthy cells and target cancer cells.

The PARP enzyme has a wide range of functions in a cell, such as DNA damage response, regulation of transcription, and apoptosis. PARP inhibitors exploit the concept of synthetic lethality. In this lethal phenomenon, cell can survive an isolated genetic event, whereas cell death occurs in the case of co-occurrence of multiple genetic events. They target cancer cells that have a defective homologous recombination DNA repair pathway.

The growing emphasis on enhancing the efficacy of PARP inhibitors owing to the increasing prevalence of cancer further supports the market expansion. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. The American Cancer Society estimated that in 2024, 12,740 women are expected to die due to ovarian cancer, and 19,680 new cases will be diagnosed in the United States.

Rising Cases of Breast Cancer Boost Market Demand

As per National Breast Cancer Foundation, one out of eight women will be diagnosed with breast cancer over the course of their lifetime. It was estimated that in 2023, 297,790 women and 2,800 men will get a diagnosis of invasive breast cancer. PARP inhibitors prevent the cancer cells from repairing damaged tumor DNA. Olaparib is used for the treatment of both early and metastatic breast cancer, and Talazoparib is used for the treatment of metastatic breast cancer.

Due to the growing prevalence of the disease, various organizations are providing additional funding to research institutions for better treatments and better prediction models for breast cancer. For instance, In November 2023, researchers from University of Washington, Seattle Children's Cancer Consortium and Fred Hutchinson received additional funding from Breast Cancer Research Foundation (BCRF) to continue working on their ongoing studies. The Vice President for Clinical Affairs and a medical oncologist, Davidson received funding for another year to research the expanded applications of PARP inhibitors.

Increasing Research Activities Support the PARP Inhibitors Market Growth

PARP inhibitors have shown promising results since their clinical applications and were the first clinically approved drugs that were developed based on synthetic lethality. The inhibitors have been approved for use as maintenance treatment for cancer patients with BRCA mutations. The continuation of innovative explorations is expected to support the development of potent drugs with novel mechanisms.

In 2023, the American Society of Clinical Oncology (ASCO) presented new updates on the utilization of PARP inhibitors for the treatment of ovarian cancer. Significant attempts are being made to combine PARP inhibitors with immune checkpoint inhibitors (ICIs) in patients suffering from advanced ovarian cancer. It was demonstrated in the DUO-O trial that the addition of maintenance Olaparib and anti-programmed death-ligand 1 (PD-L1) immune checkpoint inhibitor durvalumab to the standard of care prolongs progression free survival in cases on advanced ovarian cancer. PARP inhibitors present a promising avenue in the therapy for ovarian cancer. Ongoing research and development activities for novel agent combinations hold promise for future advancements.

North America Expected to Account for a Significant Market Share

The strong presence of various key players in the region, availability of skilled workforce, increasing government initiatives to strengthen the healthcare sector, and rising investments towards research and development activities by both research institutions and market players is supporting the expansion of the North America PARP inhibitors market. According to American Cancer Society, in 2023, 1,958,310 new cancer cases and 609,820 cancer related deaths were estimated to occur in the United States. Due to the surge in cases of cancer in the region, the requirement for advanced cancer therapeutics, including PARP inhibitors is increasing. The different regulatory bodies in the country are focusing on studying the effects of novel cancer treatments and granting them approvals.

In 2023, Pfizer, Inc., one of the leading pharmaceutical and biotechnology corporations in the United States, announced positive results from their phase 3 TALAPRO-2 study of TALZENNA (Talazoparib), an oral PARP inhibitor, combined with enzalutamide. They demonstrated a clinically meaningful and statistically significant improvement in radiographic progression free survival, with or without HRR gene mutations. The United States Food and Drug Administration (FDA) granted priority review of TALZENNA combined with enzalutamide for treatment of men with metastatic castration-resistant prostate cancer.

Preference for Olaparib Anticipated to Increase

Increasing adoption of Olaparib PARP inhibitors for treatment of pancreatic cancer, ovarian cancer, and both metastatic and early breast cancer is facilitating the market growth. In 2022, an article published in Cancer Discovery discussed the 5-year analysis of data, showing that the patients that received Olaparib for 2 years had a median progression free survival of 3.5 years longer than those who received placebo.

In January 2024, the post-hoc analysis of phase 3 PROpel trial (NCT03732820) presented at the 2024 Genitourinary Cancers Symposium confirmed that the treatment with frontline Olaparib and abiraterone acetate benefits patients with HRR mutated metastatic castration-resistant prostate cancer. The post-hoc exploratory analysis that examined the aggregate subgroups of non-BRCA-mutated, BRCA-mutate, non-HRR-mutated, and HRR-mutated disease further demonstrated favorable radiographic progression free survival outcomes with abiraterone plus Olaparib as opposed to abiraterone alone.

Retail Pharmacies Expected to Witness Significant Growth

The provision of branded as well as generic drugs, with other pharmaceutical products under one roof is bolstering the popularity of retail pharmacies in various regions across the globe. The pharmacists in these pharmacies are trusted counsel by many and often explain the side effects of different drugs to their customers. These pharmacies are an integral component of the healthcare ecosystem in various countries across the globe, accounting for a significant PARP inhibitors market share.

Meanwhile, online pharmacies are expected to rapidly expand in the coming years. The growth can be attributed to providing various benefits by online pharmacies, including privacy, discounts, fast shipping, delivery, convenience, and others. The online purchase of medicines from verified and legitimate internet pharmacies has become an accepted practice among various developed countries.

Future Market Scenario (2024 - 2031F)

Various clinical trials are underway to investigate the next generation of PARP inhibitors. PARP enzymes play different roles at different cell cycle stages, therefore, it is essential to understand the interaction network in the cells for the exploration of novel potential therapies.

Additional studies are required for determining if alternating drug combinations, including PARP inhibitors, anti-angiogenic agents, and immunotherapy are able to offer clinical benefits to patients suffering from ovarian cancer.

Recently, in RUBY Part 2 Phase 3 trial it was noted that the combination of Zejula (niraparib) and Jemperli (dostarlimab) significantly improved progression-free survival in recurrent or primary advanced endometrial cancer. The results have reinforced the development approach of using Jemperli in immuno-oncology-based combination therapies.

Key Players Landscape and Outlook

Key participants in global PARP inhibitors market include Pfizer, Inc., GlaxoSmithKline Plc., Genentech, Inc., AbbVie Inc., and Sierra Oncology, Inc. The rising investments towards research and development activities and increasing prevalence of different types of cancer is providing lucrative growth opportunities to the market.

In 2023, FDA approved Pfizer drug, Talazoparib (Talzenna) with enzalutamide for HRR gene mutated metastatic castration-resistant prostate cancer. The efficacy of the drug was evaluated in a multi-cohort, randomized, placebo-controlled, and double-blind trial that enrolled 399 patients with homologous recombination repair gene mutated metastatic castration-resistant prostate cancer.

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global PARP Inhibitors Market Outlook, 2017-2031F

4.1. Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2. By Drug Type
- 4.2.1. Olaparib
- 4.2.2. Niraparib
- 4.2.3. Rucaparib
- 4.2.4. Talazoparib
- 4.2.5. Veliparib
- 4.2.6. Others
4.3. By Application
- 4.3.1. Ovarian Cancer
- 4.3.2. Breast Cancer
- 4.3.3. Pancreatic Cancer
- 4.3.4. Prostate Cancer
4.4. By End-user
- 4.4.1. Specialty Clinics
- 4.4.2. Hospitals
- 4.4.3. Home Healthcare
- 4.4.4. Others
4.5. By Distribution Channel
- 4.5.1. Hospital Pharmacies
- 4.5.2. Retail Pharmacies
- 4.5.3. Online Pharmacies
4.6. By Region
- 4.6.1. North America
- 4.6.2. South America
- 4.6.3. Europe
- 4.6.4. Asia-Pacific
- 4.6.5. Middle East & Africa
4.7. By Company Market Share (%), 2023

5. Global PARP Inhibitors Market Outlook, By Region, 2017-2031F

5.1. North America*
- 5.1.1. Market Size & Forecast
  - 5.1.1.1. By Value
  - 5.1.1.2. By Volume
- 5.1.2. By Drug Type
  - 5.1.2.1. Olaparib
  - 5.1.2.2. Niraparib
  - 5.1.2.3. Rucaparib
  - 5.1.2.4. Talazoparib
  - 5.1.2.5. Veliparib
  - 5.1.2.6. Others
- 5.1.3. By Application
  - 5.1.3.1. Ovarian Cancer
  - 5.1.3.2. Breast Cancer
  - 5.1.3.3. Pancreatic Cancer
  - 5.1.3.4. Prostate Cancer
- 5.1.4. By End-user
  - 5.1.4.1. Specialty Clinics
  - 5.1.4.2. Hospitals
  - 5.1.4.3. Home Healthcare
  - 5.1.4.4. Others
- 5.1.5. By Distribution Channel
  - 5.1.5.1. Hospital Pharmacies
  - 5.1.5.2. Retail Pharmacies
  - 5.1.5.3. Online Pharmacies
- 5.1.6. United States*
  - 5.1.6.1. Market Size & Forecast
  - 5.1.6.1.1. By Value
  - 5.1.6.1.2. By Volume
  - 5.1.6.2. By Drug Type
  - 5.1.6.2.1. Olaparib
  - 5.1.6.2.2. Niraparib
  - 5.1.6.2.3. Rucaparib
  - 5.1.6.2.4. Talazoparib
  - 5.1.6.2.5. Veliparib
  - 5.1.6.2.6. Others
  - 5.1.6.3. By Application
  - 5.1.6.3.1. Ovarian Cancer
  - 5.1.6.3.2. Breast Cancer
  - 5.1.6.3.3. Pancreatic Cancer
  - 5.1.6.3.4. Prostate Cancer
  - 5.1.6.4. By End-user
  - 5.1.6.4.1. Specialty Clinics
  - 5.1.6.4.2. Hospitals
  - 5.1.6.4.3. Home Healthcare
  - 5.1.6.4.4. Others
  - 5.1.6.5. By Distribution Channel
  - 5.1.6.5.1. Hospital Pharmacies
  - 5.1.6.5.2. Retail Pharmacies
  - 5.1.6.5.3. Online Pharmacies
- 5.1.7. Canada
- 5.1.8. Mexico

All segments will be provided for all regions and countries covered

5.2. Europe
- 5.2.1. Germany
- 5.2.2. France
- 5.2.3. Italy
- 5.2.4. United Kingdom
- 5.2.5. Russia
- 5.2.6. Netherlands
- 5.2.7. Spain
- 5.2.8. Turkey
- 5.2.9. Poland
5.3. Asia-Pacific
- 5.3.1. India
- 5.3.2. China
- 5.3.3. Japan
- 5.3.4. Australia
- 5.3.5. Vietnam
- 5.3.6. South Korea
- 5.3.7. Indonesia
- 5.3.8. Philippines
5.4. South America
- 5.4.1. Brazil
- 5.4.2. Argentina
5.5. Middle East & Africa
- 5.5.1. Saudi Arabia
- 5.5.2. UAE
- 5.5.3. South Africa

6. Market Mapping, 2023

6.1. By Drug Type
6.2. By Application
6.3. By End-user
6.4. By Distribution Channel
6.5. By Region

7. Macro Environment and Industry Structure

7.1. Supply Demand Analysis
7.2. Import Export Analysis
7.3. Value Chain Analysis
7.4. PESTEL Analysis
- 7.4.1. Political Factors
- 7.4.2. Economic System
- 7.4.3. Social Implications
- 7.4.4. Technological Advancements
- 7.4.5. Environmental Impacts
- 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5. Porter's Five Forces Analysis
- 7.5.1. Supplier Power
- 7.5.2. Buyer Power
- 7.5.3. Substitution Threat
- 7.5.4. Threat from New Entrant
- 7.5.5. Competitive Rivalry

8. Market Dynamics

8.1. Growth Drivers
8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

9.1. Patent Landscape
9.2. Regulatory Approvals
9.3. Innovations/Emerging Technologies

10. Key Players Landscape

10.1. Competition Matrix of Top Five Market Leaders
10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4. SWOT Analysis (For Five Market Players)
10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

13.1. Pfizer, Inc.
- 13.1.1. Company Details
- 13.1.2. Key Management Personnel
- 13.1.3. Products & Services
- 13.1.4. Financials (As reported)
- 13.1.5. Key Market Focus & Geographical Presence
- 13.1.6. Recent Developments
13.2. GlaxoSmithKline Plc.
13.3. Genentech, Inc.
13.4. AbbVie Inc.
13.5. Sierra Oncology, Inc.
13.6. Ono Pharmaceutical Co. Ltd.
13.7. Johnson & Johnson Services, Inc.
13.8. Jiangsu Hengrui Medicine Co., Ltd.
13.9. Repare Therapeutic, Inc.
13.10. Karyopharm Therapeutics Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

PARP阻害剤の世界市場の評価：薬剤タイプ別、用途別、エンドユーザー別、流通チャネル別、地域別、機会、予測（2017年～2031年）

PARP Inhibitors Market Assessment, By Drug Type, By Application, By End-user, By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のPARP阻害剤市場の展望

第5章世界のPARP阻害剤市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global PARP Inhibitors Market Outlook, 2017-2031F

5. Global PARP Inhibitors Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

PARP阻害剤の世界市場の評価：薬剤タイプ別、用途別、エンドユーザー別、流通チャネル別、地域別、機会、予測（2017年～2031年）

PARP Inhibitors Market Assessment, By Drug Type, By Application, By End-user, By Distribution Channel By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のPARP阻害剤市場の展望

第5章 世界のPARP阻害剤市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境と産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global PARP Inhibitors Market Outlook, 2017-2031F

5. Global PARP Inhibitors Market Outlook, By Region, 2017-2031F

6. Market Mapping, 2023

7. Macro Environment and Industry Structure

8. Market Dynamics

9. Regulatory Framework and Innovation

10. Key Players Landscape

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

14. Strategic Recommendations

15. About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のPARP阻害剤市場の展望

第5章世界のPARP阻害剤市場の展望：地域別

第6章市場マッピング

第7章マクロ環境と産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項